Results 241 to 250 of about 92,469 (306)

Case Report: Discordant pancreatic inflammatory pseudotumor in a breast cancer survivor - a diagnostic dilemma. [PDF]

Front Oncol
Cao Z, Lyu X, Lu X, Zhang T.
europepmc   +1 more source

STK25 inhibits cancer‐associated fibroblast activation to overcome cetuximab resistance in colorectal cancer

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
• STK25 deficiency enhanced CAF‐mediated CRC growth via the NF‐κB/AREG/EGFR axis. • STK25 overexpression or AREG antibody overcame CAF‐mediated cetuximab resistance. • CRC patients with high STK25 and low CAFs marker levels might benefit from cetuximab treatment.
Yifan Hou, Jiangbo Chen, Hao Hao, Tongkun Song, Lin Song, Pu Xing, Kai Weng, Yumeng Ran, Xinying Yang, Xiaowen Qiao, Jie Chen, Ruibin Yao, Hong Yang, Lei Chen, Jiabo Di, Kai Xu, Xiangqian Su, Beihai Jiang   +17 more
wiley   +1 more source

Postoperative Outcomes and Strategic Refinement in Intraductal Papillary Mucinous Neoplasm Management: A Single Academic Cancer Center Experience. [PDF]

Cancer Diagn Progn
Nanashima A, Imamura N, Hiyoshi M, Tsuchimochi Y, Wada T, Hamada T, Suzuki Y, Araki Y, Hosokawa A, Kawakami H.   +9 more
europepmc   +1 more source

Spatial Multiomics Reveal Insights Into ADC Efficacy

European Journal of Immunology, Volume 56, Issue 5, May 2026.
Spatial multiomics profiling can reveal how tumor heterogeneity and microenvironment influence ADC efficacy. Combining spatial transcriptomics, proteomics, and AI‐based analysis improves the identification of tissue factors influencing therapy response.
Osman Goni, Niklas Klümper, Maria del Mar Muñiz Moreno, Markus Eckstein, Christoph Kuppe   +4 more
wiley   +1 more source

Synchronous Intra-ampullary Papillary-Tubular Neoplasm and Gallbladder Cancer. [PDF]

Cureus
Suto K, Kasahara N, Taniguchi M, Meguro Y, Aoki Y, Morishima K, Amori M, Inamura K, Kawata H, Sasanuma H, Yamaguchi H, Sata N.   +11 more
europepmc   +1 more source

Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
This study identifies dNLR≤ 3.18, AMC ≤ 0.48, IL‐6 ≤ 12.35, and squamous histology as independent predictors of improved survival in advanced cancers treated with anti‐PD‐1 therapy. A novel biomarker‐based model demonstrates high accuracy for 1‐year survival stratification, aiding clinical decision‐making.
Chunxia Feng, Ping Li, Qianhui Gu, Minbin Chen, Jinhua Gu   +4 more
wiley   +1 more source

Small Hepatoid Variant of Solid Pseudopapillary Neoplasm of the Pancreas: A Unique Case With Long-term Follow-up. [PDF]

DEN Open
Matsumoto H, Minaga K, Ueno S, Sone A, Chikugo E, Tonomura K, Nakano S, Uenoyama Y, Ono K, Yamashita Y.   +9 more
europepmc   +1 more source

Decoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma

Journal of Cellular Physiology, Volume 241, Issue 5, May 2026.
ABSTRACT Cancer cells rewire their metabolism to sustain a high proliferation rate. Sensing external cues is essential to match the metabolic fluxes of the cells to the external stimuli. As part of the glucose metabolism, the hexosamine biosynthesis pathway (HBP) is considered a nutrient‐sensing pathway. The HBP produces UDP‐GlcNAc, a key precursor for
Pegah Rahimizadeh, Richard Miallot, Chelsea De Bellis, Philippe Jolivet, Joanna Przybyl   +4 more
wiley   +1 more source

Microbiota in pancreatic ductal adenocarcinoma progression and therapy: The hidden players. [PDF]

Chin Med J (Engl)
Hu X, Kong F, Chen J, Li Z, Cai Z, Kong X.   +5 more
europepmc   +1 more source

<i>Helicobacter pylori</i> persists in pancreatic ductal adenocarcinoma despite eradication therapy. [PDF]

Ann Med Surg (Lond)
Mehmood MS, Danaf N.
europepmc   +1 more source